News Breaks |
|
|
| March 6, 2013 |
| 09:26 EDT |  | BIG, SOHU, TFM, AVAV, ECPG, AACC, BBY, HNR, PPHM, PAY, CYOU | On The Fly: Pre-market Movers
UP AFTER EARNINGS: Big Lots (BIG), up 7.2%... VeriFone (PAY), up 4.4%... ALSO HIGHER: Peregrine (PPHM), up 9.2% following initiation with Overweight rating, $2.50 target at Piper Jaffray... Harvest Natural (HNR), up 6.7% after death of Venezuelan president Hugo Chavez... Best Buy (BBY), up 4% after upgrade at Jefferies... DOWN AFTER EARNINGS: AeroVironment (AVAV), down 21.4%... The Fresh Market (TFM), down 11.2%... American Eagle (AEO), down 8.7%... ALSO LOWER: Sohu.com (SOHU), down 8.7% after after company refutes go-private report. Shares of Changyou.com (CYOU) also down 7%. |
|
|
News For BIG;PAY;PPHM;HNR;BBY;AACC;ECPG;AVAV;TFM;SOHU;CYOU From The Last 14 Days Check below for free stories on BIG;PAY;PPHM;HNR;BBY;AACC;ECPG;AVAV;TFM;SOHU;CYOU the last two weeks. |
|
|
| May 23, 2013 |
| 11:37 EDT |  | BBY | Options with decreasing implied volatility: WCRX CBST NTI BBY TSLA
|
|
| 10:08 EDT |  | PAY | On The Fly: Analyst Upgrade Summary
 Subscribe for More Information |
|
| 06:25 EDT | | PAY | VeriFone upgraded to Buy from Neutral at SunTrust
Subscribe for More Information |
|
| May 22, 2013 |
| 11:56 EDT | | BBY | Options with decreasing implied volatility: WCRX NTI PXP AMRN BBY
|
|
| 07:46 EDT |  | BBY | Best Buy results to start improving in 2H13, says RBC Capital
Subscribe for More Information |
|
| May 21, 2013 |
| 17:08 EDT | | BIG | Big Lots says SEC completed investigation
Subscribe for More Information |
|
| 12:36 EDT |  | BBY | On The Fly: Midday Wrap
Subscribe for More Information |
|
| 12:32 EDT | | BBY | Options with decreasing implied volatility: PXP ARNA BBY OPK CSC
|
|
| 10:20 EDT |  | BBY | Best Buy down over 3% in volatile trading, levels to watch
Subscribe for More Information |
|
| 09:25 EDT | | BBY | On The Fly: Pre-market Movers
Subscribe for More Information |
| |
| 07:09 EDT | | BBY | Best Buy expects investment in price competitiveness to continue into Q2
Subscribe for More Information |
|
| 07:07 EDT | | BBY | Best Buy reports Q1 SSS fell 1.3%
Subscribe for More Information |
|
| 07:03 EDT |  | BBY | Best Buy reports Q1 adjusted EPS 32c, consensus 25c
Reports Q1 revenue $9.38B, may not compare to consensus $10.64B. Reports Q1 SSS down 1.3%. |
|
| May 20, 2013 |
| 16:01 EDT | | TFM | The Fresh Market names Ackerman CFO
Subscribe for More Information |
|
| 15:22 EDT | | BBY | Notable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Home Depot (HD), consensus 77c; Medtronic (MDT), consensus $1.03; The TJX Companies (TJX), consensus 62c; AutoZone (AZO), consensus $7.23; Best Buy (BBY), consensus 25c; Dick's Sporting Goods (DKS), consensus 48c; Tidewater (TDW), consensus 61c; Saks (SKS), consensus 19c; Rexnord (RXN), consensus 31c; Monro Muffler Brake (MNRO), consensus 25c. |
|
| 15:05 EDT | | BBY | Best Buy May 27 weekly straddle priced for 9.1% move into Q1
Subscribe for More Information |
|
| 12:24 EDT | | BBY | Stocks with call strike movement; FSLR BBY
Subscribe for More Information |
|
| 11:08 EDT | | BBY | Best Buy May weekly volatility elevated at 117 into Q1
Subscribe for More Information |
|
| 09:58 EDT |  | SOHU | Rumor of Baidu in search deal with Sohu may be true, Forbes says
Rumors, citing an industry source, that Baidu (BIDU) has reached an agreement to purchase Sogou from Sohu.com (SOHU) in a complex swap transaction might be true, despite seemingly contradictory indications from Charles Zhang that seem to say that Sogou isn’t for sale, according to Forbes contributor Doug Young. Reference Link |
|
| 08:50 EDT | | PPHM | Peregrine reaches agreement with FDA on Phase 3 trial design for Bavituximab
Peregrine Pharmaceuticals announced that it has reached agreement with the FDA on a Phase III registration trial design of the company's lead clinical immunotherapeutic candidate bavituximab in second-line non-small cell lung cancer. The trial design was supported by promising data from a Phase IIb trial in patients treated with bavituximab plus docetaxel. The Phase III clinical trial will be a randomized, double-blind, placebo-controlled trial evaluating bavituximab plus docetaxel versus docetaxel alone enrolling approximately 600 patients at sites worldwide. The trial will enroll Stage IIIB/IV non-squamous, NSCLC patients who have progressed after standard front-line treatment. The primary endpoint of the trial will be overall survival. |
| |
|
|
|
|
